Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report released on Wednesday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Down 0.3 %

Shares of NASDAQ:EGRX opened at $5.72 on Wednesday. The company has a market cap of $74.30 million, a price-to-earnings ratio of 4.85 and a beta of 0.51. The company has a 50-day moving average price of $4.71 and a 200-day moving average price of $5.01. Eagle Pharmaceuticals has a 12 month low of $3.21 and a 12 month high of $23.52.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Eagle Pharmaceuticals by 0.4% during the first quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock valued at $3,358,000 after buying an additional 2,630 shares during the period. Headlands Technologies LLC increased its position in shares of Eagle Pharmaceuticals by 75.7% during the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock valued at $35,000 after buying an additional 2,861 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Eagle Pharmaceuticals by 623.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,841 shares of the specialty pharmaceutical company’s stock valued at $36,000 after buying an additional 5,896 shares during the period. DGS Capital Management LLC purchased a new position in shares of Eagle Pharmaceuticals during the fourth quarter valued at about $60,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in shares of Eagle Pharmaceuticals during the first quarter valued at about $83,000. 85.36% of the stock is owned by institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.